Darier disease, commonly known as keratosis follicularis, is a skin condition that causes warty lesions all over the body triggered by a genetic mutation. It is inherited in an autosomal dominant way and is caused by a mutation in the ATP2A2 gene. Rough bumps (papules) or plaques, which may be greasy or develop a brown or yellow crust on the skin, are among the symptoms of Darier disease. Furthermore, scalp, forehead, upper arms, chest, back, knees, elbows, and behind the ear are the most typical areas for blemishes. Nail abnormalities, such as red and white streaks in the nails with an unusual texture, and small pits in the palms of the hands and soles of the feet, are other signs of the disease.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future, owing to the demand for vaccine and drugs for the treatment of COVID-19. This, in turn, is expected to have a significant impact on the Darier disease drugs market.
Top Impacting Factors
Rise in demand for novel treatment, huge investment on research and development activities to develop novel therapies for Darier disease are some factors boosting market growth of the Darier disease market.
Furthermore, huge financial support to the researchers for developing novel intervention and the emergence of dermatological preparations used to treat complication associated with Darier disease boost the market growth.
In addition, increase in healthcare expenditure, collaborations & partnerships between key players to facilitate drug development, rise in R & D to improve quality of drugs, launches of novel developed drug in market and are some factors which boost the market growth.
According to the U.S. National Library of Medicine, in April 2021, the prevalence of Darier disease is estimated to be 1 in 30,000 people in Scotland, and 1 in 36,000 people in northern England, and 1 in 100,000 people in Denmark. Moreover, rise in population and increase in awareness toward Darier disease act as key drivers of the Darier disease drug market.
Market Trends
New Product Launches to Flourish the Market
In August 2019, Recursion Pharmaceuticals Inc. is conducting pre-clinical trial study for its undisclosed research project. If trial successful, it will open up the possibility of near-term testing of undisclosed research project in patients with Darier disease.
In January 2019, BridgeBio Inc. secured $299.2 million from their principal investors KKR and Viking investors for developing a novel molecule to target genetic disorders in multiple therapeutic areas, including genetic dermatology, oncology, and neurology. This fund will support the existing drug research and development plans and expand the company’s genetic portfolio.
Key Benefits of the Report
- This study presents the analytical depiction of the Darier disease drugs industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Darier Disease Drugs Market Report
- Which are the leading players active in the Darier disease drugs market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "Darier disease drugs market"?
- What is "Darier disease drugs market” prediction in the future?
- Who are the leading global players in the "Darier disease drugs market"?
- What are the current trends and predicted trends?
- What are the key benefits of the “Darier disease drugs market" report?
Darier Disease Drugs Market, by Treatment Report Highlights
| Aspects | Details |
 By Treatment |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | Sun Pharmaceutical Industries Ltd., Bridge Bio Inc., Novartis AG, Glenmark Pharmaceuticals Inc., Galderma Laboratories L.P., Mayne Pharma Group Limited, Nimble Pharmaceuticals, Bausch Health, Recursion Pharmaceuticals Inc., ALLERGAN |
Loading Table Of Content...
